Punch & Associates Investment Management Inc. Acquires New Position in iRadimed Corporation $IRMD

Punch & Associates Investment Management Inc. acquired a new stake in iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 20,000 shares of the medical equipment provider’s stock, valued at approximately $1,911,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new position in shares of iRadimed during the second quarter worth approximately $1,834,000. Man Group plc bought a new position in iRadimed in the second quarter worth approximately $1,514,000. Jupiter Topco LLC purchased a new position in iRadimed during the 2nd quarter worth $296,000. Hsbc Holdings PLC purchased a new position in iRadimed during the 2nd quarter worth $1,130,000. Finally, PDT Partners LLC bought a new stake in iRadimed during the 2nd quarter valued at $230,000. 92.34% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IRMD has been the subject of several research reports. Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $87.47 on Thursday. The stock has a market capitalization of $1.12 billion, a P/E ratio of 48.87 and a beta of 0.90. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90. The business has a fifty day moving average price of $93.16 and a 200 day moving average price of $94.29.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts anticipate that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s payout ratio is presently 44.69%.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares in the company, valued at $195,922,500. The trade was a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is currently owned by company insiders.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.